Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HEMP Hemp, Inc. Consultant Agreement With HQ Global Education, Inc. to Further Company's Hemp CBD Extraction Infrastructure to Capture Billion Dollar CBD Market https://globenewswire.com/news-release/2018/03/21/1443565/0/en/Hemp-Inc-Consultant-Agreement-With-HQ-Global-Education-Inc-to-Further-Company-s-Hemp-CBD-Extraction-Infrastructure-to-Capture-Billion-Dollar-CBD-Market.html
$MJNA Medical Marijuana, Inc. CEO Dr. Titus Presents Role of Company in Growing Industry
$MJNA Medical Marijuana, Inc. Subsidiary Kannaway(R) Announces New Powder Protein Shake and Hemp Pet Products
https://www.nasdaq.com/press-release/medical-marijuana-inc-and-subsidiary-kannaway-announces-january-2018-as-the-largest-revenue-sales-20180206-00804
$KNDI Kandi Electric Vehicle model KD08e at Prosser's Premium RV Outlet
$MJNA Medical Marijuana, Inc. Subsidiary HempMeds(R) Brasil Hosted Cannabis Symposium for Brazilian Doctors at Offices in San Diego https://www.epicos.com/article/152282/medical-marijuana-inc-subsidiary-hempmedsr-brasil-hold-its-second-doctor-symposium
$MJNA Medical Marijuana, Inc. Subsidiary HempMeds(R) Brasil Hosted Cannabis Symposium for Brazilian Doctors at Offices in San Diego https://www.epicos.com/article/152282/medical-marijuana-inc-subsidiary-hempmedsr-brasil-hold-its-second-doctor-symposium
$MJNA Medical Marijuana, Inc. Subsidiary Phyto Animal Health Named Ian Quinn as CEO https://www.medicalmarijuanainc.com/medical-marijuana-inc-subsidiary-phyto-animal-health-names-ian-quinn-ceo/
$MJNA Medical Marijuana, Inc. Named a Top 3 Hemp Producer of 2018
https://www.medicalmarijuanainc.com/medical-marijuana-inc-named-top-3-hemp-producer-2018/
$MJNA Medical Marijuana, Inc. Named a Top 3 Hemp Producer of 2018
https://www.medicalmarijuanainc.com/medical-marijuana-inc-named-top-3-hemp-producer-2018/
$HEMP Hemp, Inc. Recognized by Financial News Source TheStreet as Hemp Legalization Bill Gains Momentum https://www.nasdaq.com/press-release/hemp-inc-recognized-by-financial-news-source-thestreet-as-hemp-legalization-bill-gains-momentum-20180508-00293
$HEMP Hemp, Inc. Recognized by Financial News Source TheStreet as Hemp Legalization Bill Gains Momentum https://www.nasdaq.com/press-release/hemp-inc-recognized-by-financial-news-source-thestreet-as-hemp-legalization-bill-gains-momentum-20180508-00293
$MJNA has 85 employees. Medical Marijuana, Inc., an investment holding company, operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company licenses its proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal cannabinoid industry. It engages in the research and development of cannabinoid-based pharmaceuticals; and marketing and distribution of cannabidiol hemp oil-based products. In addition, the company provides management support and services to cooperatives, collectives, health and wellness facilities, and medical clinics; and consulting and securities services to businesses and individuals in the legal cannabis industry. Further, it focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products. Medical Marijuana, Inc. was formerly known as Hemp Deposit Distribution Corp. and changed its name to Medical Marijuana, Inc. in March, 2011. Enormous Market cap at $328.701 Million. Has total cash of $2.31 Million. The company was incorporated in 2003 and is headquartered in Poway, California. Undervalued Cannabis & Hemp Pipeline: https://www.medicalmarijuanainc.com/
$MJNA has 85 employees. Medical Marijuana, Inc., an investment holding company, operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company licenses its proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal cannabinoid industry. It engages in the research and development of cannabinoid-based pharmaceuticals; and marketing and distribution of cannabidiol hemp oil-based products. In addition, the company provides management support and services to cooperatives, collectives, health and wellness facilities, and medical clinics; and consulting and securities services to businesses and individuals in the legal cannabis industry. Further, it focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products. Medical Marijuana, Inc. was formerly known as Hemp Deposit Distribution Corp. and changed its name to Medical Marijuana, Inc. in March, 2011. Enormous Market cap at $328.701 Million. Has total cash of $2.31 Million. The company was incorporated in 2003 and is headquartered in Poway, California. Undervalued Cannabis & Hemp Pipeline: https://www.medicalmarijuanainc.com/
$KNDI Kandi’s First Three Pure Electric American Prototypes in Transit https://globenewswire.com/news-release/2018/07/02/1532434/0/en/Kandi-s-First-Three-Pure-Electric-American-Prototypes-in-Transit.html
$KNDI Kandi’s First Three Pure Electric American Prototypes in Transit https://globenewswire.com/news-release/2018/07/02/1532434/0/en/Kandi-s-First-Three-Pure-Electric-American-Prototypes-in-Transit.html
$INSY INSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical Trial https://globenewswire.com/news-release/2018/04/26/1488081/0/en/INSYS-Therapeutics-and-University-of-California-UC-San-Diego-Center-for-Medicinal-Cannabis-Research-to-Collaborate-on-Clinical-Trial.html
$INSY INSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical Trial https://globenewswire.com/news-release/2018/04/26/1488081/0/en/INSYS-Therapeutics-and-University-of-California-UC-San-Diego-Center-for-Medicinal-Cannabis-Research-to-Collaborate-on-Clinical-Trial.html
$INSY Unwavering Commitment to R&D as Company’s Driving Force
INSYS has invested approximately $250 million in research and development (R&D) since 2014, including nearly $140 million in 2016 and 2017.
Our company has advanced a new R&D vision, commencing a shift of resources from opioids to a clear, internal focus on cannabinoids, including clinical trials in infantile spasms (Phase 3), childhood absence epilepsy (Phase 2) and Prader-Willi syndrome (Phase 2), as well as the collaboration in autism research with UC San Diego’s Center for Medicinal Cannabis Research. Additional research partnerships under consideration include addiction, childhood schizophrenia/early psychosis and post-traumatic stress disorder (PTSD).
Consistent with our mission to serve the interests of patients in need of innovative therapies, our company has prioritized research programs of two life-saving investigational products (naloxone and epinephrine) as part of fulfilling our commitment to be a socially-responsible, healthcare community citizen.
Initial clinical trials of these two product candidates—naloxone nasal spray for opioid overdose and epinephrine nasal spray for anaphylaxis—showed promising results, thereby providing hope for our company to file NDAs for these two life-saving potential products in 2018 and 2019, respectively.
Filing these two NDAs would support our company’s aspirational goal of filing at least one NDA per year over the next five years.
Our company continues to put behind it the significant challenges caused by the inappropriate actions of certain former employees, most of which is over four or more years ago. It is our hope that our actions can help us continue regaining the trust of the healthcare community as we focus on the matters we can control. We believe that we have established a strong foundation to accomplish our stated mission and to bring value to patients and other stakeholders we have the privilege to serve.
$INSY Unwavering Commitment to R&D as Company’s Driving Force
INSYS has invested approximately $250 million in research and development (R&D) since 2014, including nearly $140 million in 2016 and 2017.
Our company has advanced a new R&D vision, commencing a shift of resources from opioids to a clear, internal focus on cannabinoids, including clinical trials in infantile spasms (Phase 3), childhood absence epilepsy (Phase 2) and Prader-Willi syndrome (Phase 2), as well as the collaboration in autism research with UC San Diego’s Center for Medicinal Cannabis Research. Additional research partnerships under consideration include addiction, childhood schizophrenia/early psychosis and post-traumatic stress disorder (PTSD).
Consistent with our mission to serve the interests of patients in need of innovative therapies, our company has prioritized research programs of two life-saving investigational products (naloxone and epinephrine) as part of fulfilling our commitment to be a socially-responsible, healthcare community citizen.
Initial clinical trials of these two product candidates—naloxone nasal spray for opioid overdose and epinephrine nasal spray for anaphylaxis—showed promising results, thereby providing hope for our company to file NDAs for these two life-saving potential products in 2018 and 2019, respectively.
Filing these two NDAs would support our company’s aspirational goal of filing at least one NDA per year over the next five years.
Our company continues to put behind it the significant challenges caused by the inappropriate actions of certain former employees, most of which is over four or more years ago. It is our hope that our actions can help us continue regaining the trust of the healthcare community as we focus on the matters we can control. We believe that we have established a strong foundation to accomplish our stated mission and to bring value to patients and other stakeholders we have the privilege to serve.
$INSY INSYS Therapeutics Provides an Update on Its Ongoing Transformation https://globenewswire.com/news-release/2018/06/18/1526034/0/en/INSYS-Therapeutics-Provides-an-Update-on-Its-Ongoing-Transformation.html
$INSY INSYS Therapeutics Provides an Update on Its Ongoing Transformation https://globenewswire.com/news-release/2018/06/18/1526034/0/en/INSYS-Therapeutics-Provides-an-Update-on-Its-Ongoing-Transformation.html
$AMGN and 3 Drug and Biotech Stocks Awaiting FDA Decisions in July https://investorplace.com/2018/07/4-drug-biotech-stocks-awaiting-fda-decisions-july-ggsyn/ $AMGN $GSK $INSY $JNJ $VRTX $INVVY https://investorplace.com/2018/07/4-drug-biotech-stocks-awaiting-fda-decisions-july-ggsyn/
$JNJ and 3 Drug and Biotech Stocks Awaiting FDA Decisions in July https://investorplace.com/2018/07/4-drug-biotech-stocks-awaiting-fda-decisions-july-ggsyn/ $AMGN $GSK $INSY $JNJ $VRTX $INVVY https://investorplace.com/2018/07/4-drug-biotech-stocks-awaiting-fda-decisions-july-ggsyn/
FDA Approval Puts $GWPH GW Pharma, Three Other Cannabis-Related Names in the Spotlight https://realmoney.thestreet.com/articles/06/26/2018/fda-approval-puts-gw-pharma-three-other-cannabis-related-names-spotlight $INSY $NMUS $ZYNE
FDA Approval Puts $GWPH GW Pharma, Three Other Cannabis-Related Names in the Spotlight https://realmoney.thestreet.com/articles/06/26/2018/fda-approval-puts-gw-pharma-three-other-cannabis-related-names-spotlight $INSY $NMUS $ZYNE
Path to Profitability and Use of Proceeds
Gevo intends to use a portion of its current cash and cash equivalents to pursue its previously disclosed strategy. First, Gevo intends to deploy capital at its specialty production facility in Luverne, Minnesota (the “Luverne Facility”) to make certain changes and improvements to produce low-carbon ethanol side-by-side with low-carbon isobutanol. By focusing on low-carbon ethanol in the near term, debottlenecking production, while adapting and optimizing the Luverne Facility’s energy and equipment infrastructure to use lower amounts of lower fossil-based energy sources, Gevo believes that it can increase revenues to make the Luverne Facility profitable on a non-GAAP Cash EBITDA basis.2
Second, Gevo plans to deploy capital to continue to strategically develop its isobutanol and related hydrocarbon businesses. In addition to low-carbon ethanol production, Gevo also believes that it could become profitable on a non-GAAP Cash EBITDA basis2 if it is able to obtain binding offtake agreements for its isobutanol and related hydrocarbon products that justify an expansion of the Luverne Facility whereby, upon obtaining adequate additional funding, Gevo would convert the Luverne Facility primarily to the production of isobutanol at scale, with some percentage of such isobutanol volumes to be further processed into hydrocarbons such as its alcohol-to-jet fuel and isooctane products.
About Gevo
Gevo is a leading renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo’s strategy is to commercialize bio-based alternatives to petroleum-based products to allow for the optimization of fermentation facilities’ assets, with the ultimate goal of maximizing cash flows from the operation of those assets. Gevo produces isobutanol, ethanol and high-value animal feed at its fermentation plant in Luverne, MN. Gevo has also developed technology to produce hydrocarbon products from renewable alcohols. Gevo currently operates a biorefinery in Silsbee, TX, in collaboration with South Hampton Resources Inc., to produce renewable jet fuel, octane, and ingredients for plastics like polyester. Gevo is committed to a sustainable bio-based economy that meets society’s needs for plentiful food and clean air and water. Learn more at our website: www.gevo.com.
Path to Profitability and Use of Proceeds
Gevo intends to use a portion of its current cash and cash equivalents to pursue its previously disclosed strategy. First, Gevo intends to deploy capital at its specialty production facility in Luverne, Minnesota (the “Luverne Facility”) to make certain changes and improvements to produce low-carbon ethanol side-by-side with low-carbon isobutanol. By focusing on low-carbon ethanol in the near term, debottlenecking production, while adapting and optimizing the Luverne Facility’s energy and equipment infrastructure to use lower amounts of lower fossil-based energy sources, Gevo believes that it can increase revenues to make the Luverne Facility profitable on a non-GAAP Cash EBITDA basis.2
Second, Gevo plans to deploy capital to continue to strategically develop its isobutanol and related hydrocarbon businesses. In addition to low-carbon ethanol production, Gevo also believes that it could become profitable on a non-GAAP Cash EBITDA basis2 if it is able to obtain binding offtake agreements for its isobutanol and related hydrocarbon products that justify an expansion of the Luverne Facility whereby, upon obtaining adequate additional funding, Gevo would convert the Luverne Facility primarily to the production of isobutanol at scale, with some percentage of such isobutanol volumes to be further processed into hydrocarbons such as its alcohol-to-jet fuel and isooctane products.
About Gevo
Gevo is a leading renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo’s strategy is to commercialize bio-based alternatives to petroleum-based products to allow for the optimization of fermentation facilities’ assets, with the ultimate goal of maximizing cash flows from the operation of those assets. Gevo produces isobutanol, ethanol and high-value animal feed at its fermentation plant in Luverne, MN. Gevo has also developed technology to produce hydrocarbon products from renewable alcohols. Gevo currently operates a biorefinery in Silsbee, TX, in collaboration with South Hampton Resources Inc., to produce renewable jet fuel, octane, and ingredients for plastics like polyester. Gevo is committed to a sustainable bio-based economy that meets society’s needs for plentiful food and clean air and water. Learn more at our website: www.gevo.com.
$HEMP Hemp, Inc. Applauds Addition of Hemp Legislation to 2018 Farm Bill
LOL you sold at the bottom. Thanks for your shares. Love cheapies. you can chase my shares by friday up $.07
$MJNA Medical Marijuana, Inc. Subsidiary HempMeds® Garners National Media Coverage on TMZ Entertainment News https://www.medicalmarijuanainc.com/medical-marijuana-inc-subsidiary-hempmeds-garners-national-media-coverage-tmz-entertainment-news/
$MJNA Medical Marijuana, Inc. Subsidiary HempMeds® Garners National Media Coverage on TMZ Entertainment News https://www.medicalmarijuanainc.com/medical-marijuana-inc-subsidiary-hempmeds-garners-national-media-coverage-tmz-entertainment-news/
$KNDI The Kandi Machine -- China's Sweet Pollution Solution KNDI
$KNDI The Kandi Machine -- China's Sweet Pollution Solution KNDI
* * $KNDI Kandi Pure Electric Vehicle Product Pursuing Expansion to the American Market
Kandi Technologies Group, Inc. (the "Company," "we" or "Kandi") (NASDAQ GS:KNDI), Zhejiang JiHeKang Electric Vehicle Sales Co., Ltd. ("JiHeKang"), a 100% owned subsidiary of Kandi Electric Vehicles Group Co., Ltd (the "JV Company", a 50/50 joint venture between Kandi and Geely Group (Ningbo) Ltd.), signed a Framework Sales Agreement with Sportsman Country, LLC ("Sportsman") on June 10, 2018 for bringing its pure electric vehicles to the United States.
According to the terms, the JV Company will ship pure electric vehicle prototypes to the United States before August 10, 2018. The shipment will include Model EX3 and Model K22, which are designed for the American market in order to precede opportunity analysis and market assessment. Sportsman is responsible for all necessary application procedures for the sale of the JV Company's pure electric vehicles that are required in the United States. Detailed purchase and procurement plans will be determined based on the progress of preparation work.
Mr. Hu Xiaoming, Chairman and Chief Executive Officer of Kandi commented, "The pure electric vehicle market in the United States is full of potentials. The JV Company's EV products are competitive in price and quality. Sportsman, as the wholly owned subsidiary of the Company, is capable of growing the EV business and expanding the sales channel in the United States."
Mr. David Shan, Chairman of Sportsman said, "The electric vehicles that are manufactured by the JV Company possess a trendy appearance as well as good performance and affordable pricing; these are highly competitive in the US market. Sportsman is confident that this will be an opportunity to add variety in order to expand its product sales to maximize shareholders' value."
About Kandi Technologies Group, Inc.
Kandi Technologies Group, Inc. (KNDI), headquartered in Jinhua, Zhejiang Province, is engaged in the research and development, manufacturing and sales of various vehicle products. Kandi has established itself as one of China's leading manufacturers of pure electric vehicle ("EV") products (through its joint venture), EV parts and off-road vehicles. Kandi conducts its primary business operations through its wholly-owned subsidiary, Zhejiang Kandi Vehicles Co., Ltd. ("Kandi Vehicles"), and the partially and wholly-owned subsidiaries of Kandi Vehicles.
More information can be viewed at the Company's corporate website at http://www.kandivehicle.com. The Company routinely posts important information on its website.
* * $KNDI Kandi Pure Electric Vehicle Product Pursuing Expansion to the American Market
Kandi Technologies Group, Inc. (the "Company," "we" or "Kandi") (NASDAQ GS:KNDI), Zhejiang JiHeKang Electric Vehicle Sales Co., Ltd. ("JiHeKang"), a 100% owned subsidiary of Kandi Electric Vehicles Group Co., Ltd (the "JV Company", a 50/50 joint venture between Kandi and Geely Group (Ningbo) Ltd.), signed a Framework Sales Agreement with Sportsman Country, LLC ("Sportsman") on June 10, 2018 for bringing its pure electric vehicles to the United States.
According to the terms, the JV Company will ship pure electric vehicle prototypes to the United States before August 10, 2018. The shipment will include Model EX3 and Model K22, which are designed for the American market in order to precede opportunity analysis and market assessment. Sportsman is responsible for all necessary application procedures for the sale of the JV Company's pure electric vehicles that are required in the United States. Detailed purchase and procurement plans will be determined based on the progress of preparation work.
Mr. Hu Xiaoming, Chairman and Chief Executive Officer of Kandi commented, "The pure electric vehicle market in the United States is full of potentials. The JV Company's EV products are competitive in price and quality. Sportsman, as the wholly owned subsidiary of the Company, is capable of growing the EV business and expanding the sales channel in the United States."
Mr. David Shan, Chairman of Sportsman said, "The electric vehicles that are manufactured by the JV Company possess a trendy appearance as well as good performance and affordable pricing; these are highly competitive in the US market. Sportsman is confident that this will be an opportunity to add variety in order to expand its product sales to maximize shareholders' value."
About Kandi Technologies Group, Inc.
Kandi Technologies Group, Inc. (KNDI), headquartered in Jinhua, Zhejiang Province, is engaged in the research and development, manufacturing and sales of various vehicle products. Kandi has established itself as one of China's leading manufacturers of pure electric vehicle ("EV") products (through its joint venture), EV parts and off-road vehicles. Kandi conducts its primary business operations through its wholly-owned subsidiary, Zhejiang Kandi Vehicles Co., Ltd. ("Kandi Vehicles"), and the partially and wholly-owned subsidiaries of Kandi Vehicles.
More information can be viewed at the Company's corporate website at http://www.kandivehicle.com. The Company routinely posts important information on its website.
$HEMP Hemp, Inc. Applauds Senate Agriculture Committee for Passing Farm Bill with Hemp Legalization http://hempinc.com/hemp-inc-applauds-senate-agriculture-committee-for-passing-farm-bill-with-hemp-legalization/
$HEMP Hemp, Inc. Applauds Senate Agriculture Committee for Passing Farm Bill with Hemp Legalization http://hempinc.com/hemp-inc-applauds-senate-agriculture-committee-for-passing-farm-bill-with-hemp-legalization/